Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 253,836,480
  • Shares Outstanding, K 2,482,023
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 22,392 M
  • EBITDA $ 26,891 M
  • 60-Month Beta 0.29
  • Price/Sales 3.91
  • Price/Cash Flow 10.67
  • Price/Book 4.86

Options Overview Details

View History
  • Implied Volatility 22.05% (-0.61%)
  • Historical Volatility 31.14%
  • IV Percentile 2%
  • IV Rank 2.53%
  • IV High 53.48% on 04/10/25
  • IV Low 21.24% on 12/24/24
  • Expected Move (DTE 7) 2.05 (2.03%)
  • Put/Call Vol Ratio 0.76
  • Today's Volume 23,146
  • Volume Avg (30-Day) 54,981
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 754,082
  • Open Int (30-Day) 726,329
  • Expected Range 98.84 to 102.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 2.07
  • Number of Estimates 5
  • High Estimate 2.16
  • Low Estimate 1.98
  • Prior Year 1.72
  • Growth Rate Est. (year over year) +20.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.91 +21.68%
on 11/05/25
105.84 -4.68%
on 11/25/25
+17.03 (+20.31%)
since 11/04/25
3-Month
77.58 +30.05%
on 09/25/25
105.84 -4.68%
on 11/25/25
+16.84 (+20.04%)
since 09/04/25
52-Week
73.31 +37.62%
on 05/15/25
105.84 -4.68%
on 11/25/25
-0.48 (-0.47%)
since 12/04/24

Most Recent Stories

More News
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)

EXZOLT™ CATTLE-CA1 is the first in its class and the only product conditionally approved for both the prevention and treatment of New World screwworm and treatment and control of cattle fever tick

MRK : 100.89 (-1.35%)
1 Value Stock to Target This Week and 2 We Question

1 Value Stock to Target This Week and 2 We Question

MRK : 100.89 (-1.35%)
SBH : 15.54 (+0.97%)
APOG : 37.58 (-1.42%)
U.S. and U.K. Reach Agreement in Principle on Pharmaceutical Pricing in New Economic Prosperity Deal

The United States and the United Kingdom have reached an agreement in principle on pharmaceutical pricing as part of the new U.S.–U.K. Economic Prosperity Deal, aimed at addressing long-standing pricing...

MRK : 100.89 (-1.35%)
PFE : 25.70 (+0.51%)
GSK : 48.57 (-0.82%)
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

Merck granted Fast Track Designation by the U.S. FDA for MK-2214 for the treatment of Alzheimer's disease

MRK : 100.89 (-1.35%)
Merck & Co. Stock: Is MRK Outperforming the Healthcare Sector?

Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately optimistic about its prospects.

XLV : 153.90 (-0.76%)
MRK : 100.89 (-1.35%)
PFE : 25.70 (+0.51%)
Merck to Participate in the Citi 2025 Global Healthcare Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global...

MRK : 100.89 (-1.35%)
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Chirfi Guindo, chief marketing officer, Human Health, and Dr. Eliav Barr, senior vice president, head of global...

MRK : 100.89 (-1.35%)
2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

QCOM : 174.35 (-0.41%)
MRK : 100.89 (-1.35%)
Stocks making big moves yesterday: Meta, Tenet Healthcare, Wynn Resorts, Elevance Health, and Merck

Stocks making big moves yesterday: Meta, Tenet Healthcare, Wynn Resorts, Elevance Health, and Merck

META : 661.53 (+3.43%)
MRK : 100.89 (-1.35%)
WYNN : 125.72 (-4.42%)
THC : 212.14 (+0.38%)
ELV : 333.49 (+0.83%)
Stocks Finish Sharply Higher as Tech Stocks Soar

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up by +1.55%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up by +0.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up by +2.62%. December...

AMAT : 269.44 (+0.30%)
GOOGL : 317.62 (-0.63%)
MDLZ : 55.80 (-0.41%)
AAPL : 280.70 (-1.21%)
FRO : 23.24 (-1.53%)
AVGO : 381.03 (+0.11%)
MRK : 100.89 (-1.35%)
$IUXX : 25,581.70 (-0.10%)
LITE : 327.85 (+8.21%)
ELV : 333.49 (+0.83%)
ASML : 1,110.08 (-2.70%)
ZNH26 : 112-225 (-0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 104.21
2nd Resistance Point 103.40
1st Resistance Point 102.15
Last Price 100.89
1st Support Level 100.09
2nd Support Level 99.28
3rd Support Level 98.03

See More

52-Week High 105.84
Last Price 100.89
Fibonacci 61.8% 93.41
Fibonacci 50% 89.57
Fibonacci 38.2% 85.74
52-Week Low 73.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar